| Specialty Retail Industry | Consumer Discretionary Sector | Dr. Kandiraju Venkata Sita Ram Rao B.Tech, M.E., Ph.D. CEO | XNSE Exchange | Y2849A135 CUSIP |
| India Country | 4,057 Employees | 30 Jul 2026 Last Dividend | 23 Mar 2015 Last Split | - IPO Date |
Granules India Limited is a prominent company specializing in the pharmaceutical sector, with a focus on manufacturing and selling a broad array of products, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs). Established in 1984, the company prides itself on its strong presence both within India and on the international stage. Its headquarters are located in Hyderabad, India, positioning it strategically in one of the country's major hubs for the pharmaceutical industry. Granules India Limited caters to a diverse set of therapeutic categories, leveraging its extensive experience and innovation capabilities to address the dynamic needs of the healthcare sector.
Granules India Limited produces APIs for a variety of therapeutic uses, including anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. These ingredients are essential for the pharmaceutical industry, serving as the active components in medications that treat a wide range of diseases and conditions.
The company also specializes in the production of intermediates that are key in the formulation of pharmaceuticals. These intermediates are crucial steps in the drug manufacturing process, ultimately leading to the production of effective and safe medications.
Granules India offers a wide array of finished dosage forms, including tablets, caplets, and press-fit capsules. These are available in various packaging options such as bulk, blister packs, and bottles. The company's capability to deliver high-quality finished products makes it a vital player in the global pharmaceutical market.
In addition to its range of APIs and FDs, Granules India Limited has capabilities in manufacturing high potent products. These products require specialized handling and manufacturing processes due to their potency and are critical for treating certain health conditions.
The company also offers products for oncology, addressing the growing global need for effective cancer treatments. This includes the development and manufacturing of drugs designed to meet the specific requirements of oncology patients, showcasing Granules India Limited's commitment to contributing to the fight against cancer.